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Abstract
Background: Illicit drug use is common and known to cause and exacerbate a wide spectrum of kidney disease,
often leading to end-stage renal disease (ESRD), but little is known about its prevalence or associated mortality
among incident hemodialysis patients.
Methods: This study is a retrospective cohort analysis using data obtained from the United States Renal Data
System. We assembled a cohort of 511,821 incident hemodialysis patients age 20 years and older who initiated
hemodialysis between January 1, 2006 and December 31, 2010. Illicit drug dependence was defined by comorbidity
on the ESRD Medical Evidence Report (Form CMS-2728). We performed survival analysis to examine the association
of drug dependence with overall mortality and mortality due to diagnoses that can be associated with intravenous
drug use (drug-sensitive diagnoses) in the first year after initiating hemodialysis.
Results: Drug dependence was recorded for 1.5 % (n = 7,461). Drug dependence was independently associated
with a 1.3-fold and 2.5-fold higher hazard of overall mortality and mortality due to a potentially drug-sensitive
diagnosis [adjusted hazard ratio (AHR) 1.34 (1.27–1.41) and 2.54 (2.05–3.14), p < 0.001, respectively]. This association
varied significantly by age (pinteraction < 0.001), with a 9-fold higher hazard of mortality due to a potentially
drug-sensitive diagnosis among the youngest patients with drug dependence [AHR 9.21 (5.15–16.44), p < 0.001].
Conclusion: Illicit drug dependence is a burden within the ESRD program and is strongly associated with
premature mortality, particularly among younger patients. Targeted intervention is needed to help reduce this
burden.
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Background
Since the passage of the Medicare End-Stage Renal Disease
(ESRD) Program entitlement in 1972, dialysis has been
transformed from a scarce resource available only to the
young and otherwise healthy to an essentially unlimited
therapy [1]. In-center hemodialysis facility availability has
kept pace with increasing numbers of incident ESRD pa-
tients [2]. There have also been improvements in dialysis
care since its inception, and mortality has declined by 28 %
among hemodialysis patients over the last two decades.
Nevertheless, little more than half are alive three years after
ESRD onset [3].
Although illicit drug use is common and known to cause
and exacerbate a wide spectrum of kidney disease often
leading to ESRD, little is known about its prevalence or as-
sociated mortality among incident hemodialysis patients
[4–6]. A better understanding of the burden of illicit drug
dependence among patients with ESRD could help identify
important targets for improving the overall morbidity and
mortality of the ESRD population. We examined the preva-
lence of and mortality associated with illicit drug depend-
ence among incident hemodialysis patients in the United
States using a national registry.* Correspondence: vanessa.grubbs@ucsf.edu
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Using data obtained from the United States Renal Data
System (USRDS), we assembled a cohort of 511,821 inci-
dent hemodialysis patients age 20 years and older who initi-
ated hemodialysis between January 1, 2006 and December
31, 2010. This study is deemed exempt from Institutional
Review Board approval because it is a secondary analysis of
de-identified data.
Primary outcomes
Our primary outcomes were mortality, overall and due to
diagnoses that can be associated with intravenous drug use
(illicit drug-sensitive diagnoses) in the first year after initi-
ation of dialysis. Patients were considered to have poten-
tially drug-related mortality if any of the first three causes
of death was attributed to valvular disease, septicemia sec-
ondary to internal vascular access, septicemia secondary to
catheter, cardiac infection (endocarditis), or drug overdose
from street drugs (Additional file 1).
Primary predictor
Our primary predictor was illicit drug dependence,
currently or within the last 10 years, as defined on the
ESRD Medical Evidence Report (Form CMS-2728).
Covariates
All covariates were defined using the Medical Evidence
Report. Covariates included age, gender, race/ethnicity,
primary cause of ESRD, Medicaid insurance, vascular ac-
cess at dialysis initiation, and nephrology care prior to
dialysis initiation. Age was categorized as 20–44, 45–64,
65–74, 75+ years. Race was categorized as white, black,
Asian, or other; we also adjusted for an indicator of His-
panic ethnicity. Primary diagnosis of ESRD was catego-
rized as diabetes, hypertension, glomerulonephropathy,
or other/unknown. Vascular access at dialysis initiation
was defined as ateriovenous fistula (AVF), ateriovenous
graft (AVG), catheter with maturing AVF, catheter with
maturing AVG, and catheter only. Duration of nephrol-
ogy care prior to dialysis initiation was categorized as
none, less than 6 months, 6–12 months, more than
12 months, or unknown. Finally, we considered Medic-
aid insurance as a proxy for socioeconomic status. Indi-
viduals were categorized as having Medicaid insurance if
Medicaid was noted as the medical coverage at the time
of dialysis initiation.
Statistical analysis
Patient characteristics were examined by drug depend-
ence using chi-square tests. We then used Cox propor-
tional hazards models to examine the association of
drug dependence with mortality overall and mortality
due to potentially drug-sensitive diagnoses in the first
year after initiating hemodialysis. To help understand
confounding of drug dependence, we sequentially added
primary cause of ESRD, pre-dialysis care and type of vas-
cular access, and finally Medicaid insurance to a base
model adjusting for age, gender, race, and Hispanic eth-
nicity. Finally, we examined the adjusted associations of
drug dependence with mortality stratified by age at
dialysis initiation and tested for interaction. Of note, we
did not adjust for laboratory measures such as serum
phosphate level or dialysis adequacy because these data
are not included in the USRDS dataset. Regardless, while
such measures may serve as markers of poor adherence
and thus predict overall mortality, we view poor adher-
ence as a potential mediator of the association between
drug dependence and mortality, not a confounder. We
used Shoenfeld residuals to assess the proportional
hazards assumption, and estimated the association with
drug dependence by quarter to examine the impact of
the violations we found. All analyses were performed
with Stata v. 14.0 (StataCorp, College Station, TX).
Results
Patient characteristics are shown in Table 1. Among the
511,821 incident hemodialysis patients aged 20 years and
older from January 1, 2006 to December 31, 2010, drug
dependence was recorded for 1.5 % (n = 7,461). The preva-
lence of drug dependence decreased over time from peak
prevalence of 1.56 % in 2006 to 1.4 % in 2010 (ptrend <
0.001) and was highest among those aged 45–64 years,
males, and blacks. Half of patients with drug dependence
had Medicaid insurance and slightly more than half had
no nephrology care prior to initiating hemodialysis
(54.6 %).
Approximately one-quarter (22.9 %) of the population
died within the study period (n = 117,326). No cause of
death was recorded for 23.3 % (n = 27,342) of deaths in
the first year. Missing cause of death was slightly more
common among those with drug dependence than those
without (27.7 % vs. 23.3 %, p < 0.001). Drug dependence
was associated with a 1.6-fold higher hazard of overall
mortality after adjusting for demographics [partially
adjusted hazard ratio (HR) 1.58 (1.50–1.67), p < 0.001]
(Table 2). The association was partially attenuated
after adjusting for other covariates, but remained statisti-
cally significant [fully adjusted HR 1.34 (1.27–1.41),
p < 0.001]. This association varied significantly by age
(pinteraction < 0.001), with the highest hazards of overall
mortality due among the youngest patients but
remaining statistically significantly higher for older
patients (Fig. 1).
Drug dependence was associated with a 2.8-fold
higher hazard of mortality from potentially illicit drug-
sensitive diagnoses after adjusting for demographics
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[partially adjusted HR 2.84, 95 % CI (2.30–3.50), p < 0.001]
(Table 2). This association was also partially attenuated
after further adjustment, but remained statistically signifi-
cant [fully adjusted HR 2.54 (2.05–3.14), p < 0.001]. As
with overall mortality, this association varied significantly
by age (pinteraction < 0.001), but with much higher hazard
ratios. The highest hazard ratios for the association of
drug dependence and mortality due to potentially drug-
sensitive diagnosis were among the youngest patients and
remained statistically significantly higher until age 65
(Fig. 2).
In our analyses of sensitivity to the proportional haz-
ards assumption, we found somewhat weaker but still
statistically significant associations of drug dependence
with both mortality endpoints in the first quarter, com-
pared to the remainder of the first year.
Discussion
Within this national registry of incident hemodialysis pa-
tients, we found that illicit drug dependence was associ-
ated with significantly higher rates of overall mortality and
mortality due to diagnoses that can be associated with
illicit drug use, particularly among younger hemodialysis
patients. Given that over 40,000 people in the United
States died of drug-induced causes in 2010—exceeding
other preventable deaths such as those from firearms or
alcohol, [7] our findings are not surprising. However, this
is the first study to our knowledge to quantify the preva-
lence of illicit drug dependence and associated mortality
in this population. Among patients under the age of 40,
drug dependence was independently associated with a 4-
to 9-fold increased hazard of dying of a potentially drug-
sensitive diagnosis. In contrast, drug dependence among
older patients does not appear to signal increased risk,
possibly because it reflects more remote exposure or
survival bias.
While almost all dialysis patients under age 40 are
expected to survive for at least one year, [8] the sharply
higher mortality rates we observed among younger drug-
dependent patients, in particular deaths due to potentially
drug-related causes, suggest that these patients comprise a
high-risk subgroup requiring targeted interventions. In our
study, 4 % (approximately 1,600) of patients under age 40
requiring renal replacement each year have illicit drug
dependence. Attention to reducing morbidity and mortality
in this population is urgently needed.
Because dialysis resources are not scarce in the United
States, it is the general consensus that any patient who clin-
ically requires renal replacement therapy and agrees to
Table 2 Hazard of one-year mortality overall or due to drug-














1.0 (reference) 1.58 (1.50–1.67) 2.84 (2.30–3.50)
Adjusted for above +
primary cause of
ESRD
1.0 (reference) 1.52 (1.44–1.60) 2.80 (2.26–3.45)





1.0 (reference) 1.39 (1.32–1.47) 2.58 (2.09–3.19)
Adjusted for above +
Medicaid insurance
1.0 (reference) 1.34 (1.27–1.41) 2.54 (2.04–3.14)
*p < 0.001 for all estimates




(N = 504,360, 98.5 %)
Drug dependence
(N = 7,461, 1.5 %)
Age group, years
< 45 56,969 (11.3) 2,427 (32.5)
45–64 118,758 (37.4) 4,655 (62.4)
65–74 121,737 (24.1) 289 (3.9)
> 74 136,896 (27.1) 90 (1.2)
Male gender 283,718 (56.2) 5,286 (70.9)
Race
White 331,019 (65.6) 2,703 (36.2)
Black 145,126 (28.8) 4,594 (61.6)
Asian 21,946 (4.3) 44 (0.6)
Other 6,269 (1.2) 120 (1.6)
Hispanic ethnicity 71,346 (14.1) 769 (10.3)
Primary cause ESRD
Diabetes 232,612 (46.1) 1,893 (25.4)
Hypertension 145,548 (28.9) 2,568 (34.4)
Glomerulonephropathy
29,422 (5.8) 637 (8.5)
Other/Unknown 96,778 (19.2) 2,363 (31.7)
Vascular access at
initiation
AVF 70,741 (14.1) 605 (8.2)
AVG 17,344 (3.5) 227 (3.1)
Catheter with
maturing AVF
78,717 (15.8) 1,048 (14.1)
Catheter with
maturing AVG
12,296 (2.5) 226 (3.0)
Catheter only 320,720 (64.2) 5,304 (71.6)
No pre-dialysis neph-
rology care
161,201 (32.0) 4,073 (54.6)
Medicaid insurance 128,990 (25.6) 3,731 (50.0)
Grubbs et al. BMC Nephrology  (2016) 17:56 Page 3 of 6
dialysis should have it. Accordingly, nearly all drug-
dependent patients in need of renal replacement therapy
receive hemodialysis. Since illicit drug use is known to
cause and exacerbate renal disease, and non-adherence to
the medical regimen is common in this population, active
drug use is considered a contraindication to renal trans-
plantation—the form of renal replacement therapy afford-
ing the best survival and quality of life [9–11].
Homelessness and inadequate housing are common in this
population, and often render peritoneal dialysis a non-
viable option for renal replacement therapy, due to the high
risk of peritonitis and lack of storage space for dialysis ma-
terials. Furthermore, injection drug use damages blood
vessels, which often destroys potential sites for permanent
vascular access. Therefore the only attainable vascular ac-
cess is often a dialysis catheter, which is not only prone to
high rates of infection, but may also be used by the injec-
tion drug user for intravenous drug use, with its inherent
risk of overdose and additional risk of infection. As a result,
drug dependent patients in need of renal replacement ther-
apy are relegated to care that places them at increased risk
of morbidity and mortality attributable to ESRD, overdose,
and infection. Further, since both transplant and peritoneal
dialysis are also considerably less costly than hemodialysis,
drug dependent patients are also given the most expensive
care—thus disproportionately contributing to the estimated
Fig. 2 Adjusted hazard ratios for the association of drug dependence with first-year mortality due to drug-sensitive diagnosis, by age at
dialysis initiation
Fig. 1 Adjusted hazard ratios for the association of drug dependence with first-year overall mortality, by age at dialysis initiation
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$11 billion annual healthcare cost attributed to illicit drug
dependence [12].
Ongoing drug use and personal behaviors common
among dialysis patients with illicit drug dependence, such
as non-adherence to a standard dialysis prescription, also
contribute to high risk of morbidity and mortality [13].
Yet there is currently no requirement that drug dependent
patients undergo treatment for their addictions. Drug re-
habilitation programs are readily accessible and consid-
ered effective treatment for drug addiction. While rates of
participation in drug rehabilitation among the dialysis
population are unknown, participation in the general
population is very low [14]. In a 2013 survey, only 13.4 %
of persons age 12 or older with illicit drug dependence or
abuse received treatment for their illicit drug use in the
past year [15]. Further, 80.9 % did not perceive a need for
treatment for their illicit drug use [15]. However involun-
tary or coerced treatment, e.g. through drug treatment
court, has been demonstrated to be effective means of
achieving sobriety and decreasing future recidivism [16].
For societal and individual benefit, the illicit drug
dependent population with ESRD should be strongly
counseled to actively participate in existing but sorely
underutilized drug treatment programs at the time of dia-
lysis initiation and as a part of ongoing dialysis care. Social
workers are available in dialysis facilities to address pa-
tients’ psychosocial issues, but the scope is often limited
to dialysis-related concerns. At the very least, dialysis pro-
viders should inform drug dependent patients of the sub-
stantial morbidity and mortality associated with their
addiction, but awareness and harm reduction programs
alone have not been shown to fully curtail continued risky
behavior [17, 18].
This study is not without limitations. We identified illicit
drug dependence using Form 2728. Ascertainment of co-
morbid conditions using this form has been shown to
have excellent specificity but lack sensitivity [19]. More-
over, the under-ascertainment of drug dependence may be
non-random, with minorities, young patients, and the
poor more likely to be asked about illicit drug use than
their white, older, and non-poor counterparts. The result-
ing under-ascertainment of drug dependence among older
patients and whites, who are both at increased mortality
risk compared to younger patients and minorities, would
likely bias our estimates of the effects of drug dependence
towards the null. Further, illicit drug dependence on Form
2728 is defined to include use within last 10 years, so that
mortality associated with current use is likely higher than
observed in our study. Similarly, Form 2728 does not as-
certain route of illicit drug use. Some illicit drug use may
only be in pill or inhaled forms, and would not entail in-
creased risk of our potentially drug-sensitive diagnoses,
with the exception of overdose. Thus the estimated 2.5-
fold higher risk of death from those diagnoses may
understate the actual increase among intravenous drug
users. In addition, cause of death was missing for approxi-
mately one-quarter of patients who died in the first year,
potentially resulting in biases either towards or away from
the null. However, such bias is unlikely to account for the
strong associations we found. Finally, we were not able to
examine hospitalization and procedure burden associated
with drug dependence because these data are collected
only on Medicare beneficiaries, whereas nearly two-thirds
(63 %) of those with drug dependence were not Medicare-
eligible by 90 days after dialysis initiation.
Conclusion
Despite these limitations, this study provides evidence of
the burden of illicit drug dependence within the ESRD
program and its strong association with mortality, par-
ticularly among younger patients. Targeted intervention
is needed to help reduce this burden.
Additional file
Additional file 1: Drug-sensitive diagnosis codes. Contains cause of
death diagnoses considered potentially drug-related. (DOCX 41 kb)
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